Skip to main
TELA

TELA Stock Forecast & Price Target

TELA Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TELA Bio is well-positioned for success in the medical technology sector due to its focus on anatomically conscious soft-tissue reconstruction solutions that prioritize the patient's natural healing response. With a growing portfolio of products specifically designed for various surgical procedures, including hernia repair and abdominal wall reconstruction, TELA Bio has a strong potential for capturing market share and generating long-term revenue. However, the company should be prepared for potential delays and challenges in the regulatory process, as seen with other synthetic mesh manufacturers facing lawsuits. It will be important for TELA Bio to prioritize compliance and maintain strong relationships with regulatory agencies to ensure timely approvals and avoid any negative impact on its operating results.

Bears say

TELA Bio is facing numerous challenges as evidenced by their recent lowered sales outlook, stock performance, and continued strategic restructuring of their US commercial team. This includes a steep deceleration in sales growth and potential disruptions as they implement new sales strategies and ramp up new hires, leading to increased losses and potential dilution for shareholders. Additionally, the company's concentrated product portfolio and heavy reliance on reimbursement for their products limit their diversification and leave them vulnerable to changes in the healthcare landscape. These fundamental reasons contribute to our negative outlook on TELA Bio's stock.

TELA has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TELA Bio, Inc. (TELA) Forecast

Analysts have given TELA a Buy based on their latest research and market trends.

According to 4 analysts, TELA has a Buy consensus rating as of Aug 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TELA Bio, Inc. (TELA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.